Darrabie MD, Arciniegas AJ, Mishra R, Bowles DE, Jacobs DO, Santacruz L. AMPK and substrate availability regulate creatine transport in cultured cardiomyocytes. Am J Physiol Endocrinol Metab 300: E870 -E876, 2011. First published March 1, 2011; doi:10.1152/ajpendo.00554.2010.-Profound alterations in myocellular creatine and phosphocreatine levels are observed during human heart failure. To maintain its intracellular creatine stores, cardiomyocytes depend upon a cell membrane creatine transporter whose regulation is not clearly understood. Creatine transport capacity in the intact heart is modulated by substrate availability, and it is reduced in the failing myocardium, likely adding to the energy imbalance that characterizes heart failure. AMPK, a key regulator of cellular energy homeostasis, acts by switching off energy-consuming pathways in favor of processes that generate energy. Our objective was to determine the effects of substrate availability and AMPK activation on creatine transport in cardiomyocytes. We studied creatine transport in rat neonatal cardiomyocytes and HL-1 cardiac cells expressing the human creatine transporter cultured in the presence of varying creatine concentrations and the AMPK activator 5-aminoimidazole-4-carboxamide-1-␤-D-ribonucleoside (AICAR). Transport was enhanced in cardiomyocytes following incubation in creatine-depleted medium or AICAR. The changes in transport were due to alterations in Vmax that correlated with changes in total and cell surface creatine transporter protein content. Our results suggest a positive role for AMPK in creatine transport modulation for cardiomyocytes in culture. myocardial creatine content; cardiac energy metabolism; adenosine 5=-monophosphate-activated protein kinase; cardiac failure CREATINE (Cr) and its phosphorylated form phosphocreatine (PCr), together with creatine kinases (CK), comprise a system that helps maintain ATP stores in cardiac and skeletal myocytes (23). During cardiac hypertrophy and heart failure, the myocardium exhibits marked changes in energy metabolism, including changes in substrate utilization, as well as in the content of high-energy metabolites. The PCr/ATP ratio decreases (9, 19 
CREATINE (Cr) and its phosphorylated form phosphocreatine (PCr), together with creatine kinases (CK), comprise a system that helps maintain ATP stores in cardiac and skeletal myocytes (23) . During cardiac hypertrophy and heart failure, the myocardium exhibits marked changes in energy metabolism, including changes in substrate utilization, as well as in the content of high-energy metabolites. The PCr/ATP ratio decreases (9, 19) , and this decline correlates with indices of cardiac function and may be a better predictor of overall and cardiovascular-related mortality than traditional indices such as ejection fraction or New York Heart Association classification (14, 15) .
The only known source of Cr to cardiac muscle is provided by the creatine transporter (CrT). CrT belongs to the SLC6 family of substrate-specific membrane transporters that also includes the serotonin, norepinephrine, and dopamine transporters (13) . CrT activity in intact hearts and L6 rat skeletal muscle cells is modulated by changes in substrate availability (3, 11) . However, the signaling mechanisms that regulate transporter activity in cardiomyocytes are poorly understood. Because of its pivotal role in cellular energy reserve systems, it is conceivable that Cr transport may be modulated by pathways that respond to changes in the overall metabolic state of the cell, such as those mediated by 5=-AMP-activated protein kinase (AMPK). AMPK activation affects energy homeostasis by switching off energy-consuming pathways in favor of processes that generate energy (8) . AMPK is expressed abundantly in cardiac muscle but is relatively inactive during normal cardiac function.
Some conditions appear to alter myocardial AMPK activity. For example, during cardiac hypertrophy or ischemia-reperfusion, AMPK becomes more active (1) , which is thought to help preserve myocardial energetics and limit myocardial injury and apoptosis (12, 17) .
We used cultured primary rat neonatal cardiomyocytes (RNCM) (4) and HL-1 cells, an immortalized murine cardiac cell line (5) , to determine whether AMPK modulates Cr transport. We report that substrate availability as well as sustained incubation in the presence of the AMPK agonist 5-aminoimidazole-4-carboxamide-1-␤-D-ribonucleoside (AICAR) modulate Cr transport in cardiomyocytes by changing the V max for Cr transport. The changes in V max correlate with changes in the amount of CrT protein.
MATERIALS AND METHODS
Plasmid constructs. cDNA encoding the human CrT was a kind gift from Dr. Marc Caron (Department of Cell Biology, Duke University). An EcoRI site followed by a Kozak sequence was added to the 5= end; an XbaI site was also introduced at the 3= end, removing the natural stop codon, and then this modified cDNA was subcloned in the mammalian expression pcDNA 3.1B vector (Invitrogen, Carlsbad, CA). Transfection of this construct results in expression of CrT protein bearing a COOH-terminal Myc/His tag that does not alter CrT function (data not shown) and was used for detection of the CrT-myc protein on Western blots. As a negative control for expression, the cDNA encoding CrT was subcloned into pcDNA3.1(ϩ) in reverse orientation with respect to the cytomegalovirus promoter.
Cell culture and expression of CrT-myc protein. RNCM were isolated and cultured as described previously (4) . All animals were treated according to protocols approved by the Duke University Institutional Animal Care and Use Committee.
HL-1 cells, an immortalized murine atrial cell line, were a kind gift of Dr. William Claycomb (Louisiana State University, New Orleans, LA). Cells were plated onto fibronectin-gelatin-coated plates and cultured in Claycomb medium (SAFC Biosciences, Lenexa, KS) supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 100 g/ml streptomycin, 0.1 mM norepinephrine, and 2 mM L-glutamine and incubated at 37°C in a humidified 5% CO 2 atmosphere as described (5) . HL-1 cells were transfected using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. For biochemical characterization of CrT protein expres-sion, HL-1 cells were cultured in six-well dishes and transfected with 4.0 g of DNA. Cr-depleted medium was prepared by extensive dialysis of fetal bovine serum using a 2-kDa dialysis cassette (Pierce Biotechnology, Rockford, IL) against sterile 150 mM NaCl. Cr concentrations in the serum were determined as described (24) . The Cr concentration in Cr-depleted medium was 0.5-1 M. Cr content in control medium was 16.6 M, which is close to Cr levels that measured in normal mice, rat, and human sera. Cr-supplemented medium was prepared by adding the appropriate volume of sterile, freshly prepared 30 mM Cr solution in water to Cr-depleted medium. This concentration closely approximates the serum levels reported for humans (0.5-1 mM) receiving Cr supplementation (16) .
[ 14 C]creatine uptake assays. Cr transport was measured in cultured cardiomyocytes as follows. Cells were washed twice with choline buffer (150 mM choline chloride, 1 mM CaCl 2, 5 mM MgCl2, 2 mM KCl, 5 mM HEPES-Tris, pH 7.5) at room temperature, followed by 10-min incubation at 37°C in a humidified 5% CO 2 14 C]creatine uptake was measured in a cholinebased (instead of sodium-based) buffer, and it was found to be negligible (50 -100 dpm/min). Uptake was terminated by aspiration of the radiolabeled solution followed by three washes with ice-cold choline buffer. The cells were lysed in 0.5 ml of 500 mM NaOH and heated to 80°C for 30 min. A 100-l aliquot of lysed cells was subjected to scintillation counting in a Beckman Coulter LS 6500 liquid scintillation counter. Protein concentration was determined using the bicinchoninic acid protein assay (Pierce Biotechnology) and bovine serum albumin as a standard.
AMPK modulation and Cr uptake. The effect of AMPK modulation on Cr transport was studied in HL-1 cells and RNCM incubated with AICAR (an activator of AMPK; EMD Biochemicals, San Diego, CA) or compound C (an inhibitor of AMPK; EMD Biochemicals). Cr transport assays were performed with sodium uptake buffer containing 15 M creatine and [
14 C]creatine and normalized to protein concentration.
Immunoblots. HL-1 cells were resuspended in ice-cold lysis buffer (150 mM NaCl, 1% Triton X-100, 50 mM Tris·HCl, pH 7.4) containing protease inhibitors (mini-Complete protease inhibitors, Roche Indianapolis, IN) and phosphatase inhibitors (5 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 2.5 mM Na2P2O7, 50 mM ␤-glycerol, 1 mM Na3VO3; Sigma, St. Louis, MO). Cell lysates were centrifuged at 4°C for 30 min at 100,000 g. Supernatants were mixed with sample buffer (125 mM Tris·HCl, pH 6.8, 20% glycerol, 6% sodium dodecyl sulfate, 10% ␤-mercaptoethanol) and then boiled for 3-5 min and subjected to SDS-PAGE in a 7.5% gel (for CrT) and transferred to nitrocellulose or polyvinylidene difluoride membranes. Blots were incubated with 150 mM NaCl, 0.05% Tween 20, 10 mM Tris·HCl, pH 7.4, and 5% (wt/vol) low-fat milk powder for 1 h at room temperature. For AMPK detection, membranes were probed with rabbit anti-AMPK␣ antibodies to detect total AMPK and rabbit anti-AMPK phosphothreonine (Thr 172 ) to detect activated AMPK at a 1:1,000 dilution. Total acetyl-CoA carboxylase (ACC; a downstream target of AMPK) and phospho-ACC were detected with 1:100 dilutions of rabbit anti-ACC or anti-phospho-ACC. For CrT-myc protein detection, the blots were probed with anti-myc antibody at a 1:5,000 dilution. The secondary antibody was horseradish peroxidase-conjugated goat anti-rabbit at a 1:10,000 dilution. TATA box-binding protein was used as a loading control on immunoblots. It was detected using a 1:1,000 dilution of mouse monoclonal antibody and purchased from AbCam (Cambridge, MA). All other primary antibodies were purchased form Cell Signaling Technology (Danvers, MA). Bands were visualized using an enhanced chemiluminescence Western blotting detection system (GE Healthcare, Piscataway, NJ). Quantitation of bands on Western blots was performed by densitometry using the Image J algorithm (National Institutes of Health, Bethesda, MD).
Labeling of cell surface protein. HL-1 cultures were grown in six-well plates and transiently transfected as described with CrT-myc or control constructs and incubated for 48 h in control growth medium, medium supplemented with 1 mM Cr, or Cr-depleted medium in the presence or absence of 0.5 mM AICAR. Cell surface proteins were biotinylated as described by Daniels and Amara (6) . Briefly, cultures were washed twice and resuspended in ice-cold PBS. The cell suspension was incubated with 10 mM sulfo-NHS-SS-Biotin (Pierce Biotechnology) at room temperature for 30 min. The reaction was quenched by ice-cold washes with PBS with 50 mM Tris (pH 8.0). Cells were lysed with RIPA buffer (150 mM NaCl, 1% deoxycholate, 1% NP-40, 0.1% SDS, 10 mM Tris·HCl, pH 7.4) containing protease inhibitors and phosphatase inhibitors, as described above. Samples were centrifuged at 4°C for 15 min at 13,400 g. Biotinylated proteins were isolated by incubation of the supernatant with UltraLink Immobilized Neutravidin (Pierce Biotechnology) for 90 min at room temperature. After extensive washing, the avidin resin was resuspended in Laemmli sample buffer containing 10% 2-mercaptoethanol and heated to 95°C for 3 min. Samples were subjected to SDS-PAGE followed by Western blot analysis, as described above. Cell surface CrT protein fraction (biotinylated CrT) was then analyzed by Western blotting using the anti-myc antibody as described above.
Kinetics and statistical analysis. Data are reported as means Ϯ SE. K m and Vmax values were derived from Michaelis-Menten plots generated using nonlinear, least-squares, curve-fitting software (version 9.0; SigmaPlot, Chicago, IL). Where indicated, ANOVA was performed followed by a Fisher's LSD test for post hoc, pairwise comparisons (version 6.0; Statistica, Tulsa, OK). Correlation was assessed using the Pearson test. Probability values Յ0.05 were considered significant.
RESULTS

Cr transport in RNCM cells and HL-1 cells is modulated by
substrate availability and incubation with AICAR. RNCM cells were cultured for 48 h in control medium (15 M), medium depleted of Cr (0.5 M), and medium supplemented with 1 mM Cr or 0.5 mM of the AMPK activator AICAR. Cr content in control medium approximates Cr levels measured in normal human serum (20 M) , whereas the concentration in Crsupplemented medium (0.5-1 mM) approximates the serum levels reported for humans receiving oral Cr supplementation (16) . Cr transport was decreased by 65% in RNCM cells (Fig. 1A) grown in medium supplemented with Cr, whereas RNCM cells cultured in medium depleted of Cr had a 47% increase in transport capacity. Incubation of RNCM cells in control medium in the presence of AICAR increased Cr transport by 89% [n ϭ 3, P Ͻ 0.05; ANOVA, Fisher's least significant difference (LSD) test]. In HL-1 cells transfected with the CrT, Cr transport responded similarly to Cr content and AICAR in the culture medium (Fig. 1B) ; incubation in the Cr-depleted medium increased Cr transport by 84%, whereas incubation in the Cr-enriched medium decreased Cr transport by 51%. As observed in RNCM, incubation of HL-1 cells in the presence of AICAR increased Cr transport by 60% (n ϭ 3, P Ͻ 0.05; ANOVA, Fisher's LSD test).
We also examined the time dependence and kinetics of transport in transfected HL-1 cells exposed to AICAR. In these cells, the response in Cr transport to Cr availability and AICAR was time dependent (Fig. 2, A and B) .
Under control conditions, Cr transport followed MichaelisMenten saturation kinetics with a V max of 5.75 Ϯ 0.7 nmol/mg protein and a K m of 42 Ϯ 8.92 M ( Table 1) . Incubation of HL-1 cells for 48 h in medium depleted of Cr increased V max 1.5-fold, whereas growth in medium enriched with Cr reduced V max by one-half relative to control conditions. Forty-eight hours of incubation in the presence of AICAR significantly increased V max in all culture conditions. There were no significant changes in substrate affinity (K m ) following incubation in medium depleted or supplemented with Cr or in the presence of AICAR ( Table 1) .
The effect of Cr availability and AICAR on the activity of AMPK was determined by quantitation of the phosphorylated Fig. 2 . Cr transport response to substrate availability or AICAR is time dependent. Cr uptake was measured in creatine transporter (CrT)-myc-transfected HL-1 cells grown in control medium plus 0.5 mM AICAR (A) or Cr-enriched (500 M) or Cr-depleted (0.5 M) culture medium (B) over time. Cr uptake was measured in nmol/mg protein and was normalized to data obtained from cells grown in control conditions. Each bar represents means Ϯ SE of 5 independent experiments performed in triplicate. *Statistically significant difference relative to control (ANOVA, Fisher's LSD, no interaction, P Ͻ 0.05). For analysis of the effect of incubation with 5-aminoimidazole-4-carboxamide-1-␤-D-ribonucleoside (AICAR), values are expressed as means Ϯ SE of 3 independent experiments in triplicate, whereas values denoting the effect of creatine (Cr) content in the medium are expressed as means Ϯ SE of 9 independent experiments in triplicate. Cr content and AICAR in the culture medium modify Cr transport capacity in HL-1 cells expressing the human creatine transporter (CrT)-myc protein. Cr transport kinetics were calculated as described in MATERIALS AND METHODS. HL-1 cultures incubated for 48 h in medium supplemented with (1 mM Cr) or depleted of Cr (0.5-1 M Cr), were compared with control medium (15 M Cr) in the presence or absence of 0.5 mM AICAR. Two-way ANOVA indicated that both Cr content and AICAR treatment independently affected Vmax (ANOVA, P Ͻ 0.05).
(activated) form of the ␣-subunit of AMPK at Thr 172 phospho-AMPK on immunoblots (8). Our results indicate that neither the content of Cr in the media nor incubation in the presence of AICAR altered the amount of the total AMPK␣ subunit (Fig. 3A) . However, AICAR increased phospho-AMPK levels relative to cells grown in control medium, Cr-supplemented medium, and Cr-depleted medium (Fig. 3B) .
Active AMPK phosphorylates ACC, and thus measurement of phospho-ACC can serve as a biological reporter of AMPK activity. We measured the effects of incubation in medium supplemented with AICAR on the levels of phospho-ACC. The results show that incubation with AICAR significantly increased phospho-ACC in cells cultured in medium depleted of Cr (Fig. 3, C and D) . Incubation of HL-1 cells in the presence of the AMPK inhibitor compound C (25) combined with AICAR blunted the increase in Cr transport observed when cultures were incubated in the presence of AICAR alone (Fig. 4) .
CrT protein expression is affected by Cr depletion, Cr supplementation, and AICAR. The effects of Cr supplementation or depletion on CrT protein expression were also studied. A 60-kDa band representing the myc-labeled CrT protein was quantitated by densitometry (Fig. 5, A and B) . This band was not detected in untransfected cells or in cells transfected with a control vector (data not shown). The transporter protein abundance was affected by Cr content in the culture medium as well as by incubation with AICAR. CrT protein was most abundant in samples isolated from cells grown in Cr-depleted medium, whereas cells incubated in medium supplemented with Cr had the smallest amount of transporter. AMPK activation increased CrT protein content in all cultures, regardless of Cr content in the medium (Table 2) . Biotinylation using membrane-impermeable NHS-SS-biotin was used to identify surface membrane proteins. These studies showed that AICAR increased the amount of CrT protein localized to the cell surface (Fig. 5C) .
The mTOR inhibitor rapamycin has no effect on Cr transport. Recently, it was reported that treatment with the mTOR inhibitor rapamycin diminished Cr transport in kidney epithelial cells (10) . We incubated RNCM cultures in the presence of 10 or 100 nM rapamycin for 4 or 24 h, followed by [ 14 C]creatine uptake assays. No significant effect on Cr transport was observed (Fig. 6 ).
DISCUSSION
In this study, we have characterized the effects of substrate availability and AICAR on Cr transport in two distinct cardiomyocyte cell lines. The failing cardiac phenotype is characterized by a shift toward a more "fetal" expression profile, encompassing increases in expression of fetal structural and contractile protein isoforms, and preferential use of glucose and lactate as energy sources over fatty acids (21) . This expression profile is similar to that observed in RNCM. RNCM cells are a primary cell culture and thus possess the native cardiac cellular signaling cascades. HL-1 cells are a wellestablished immortalized murine atrial cell line that retain the essential hallmarks of primary cardiomyocytes and are a proven expression system to study protein structure, function, and modulation of cardiomyocytes (22) . HL-1 cells have very low native Cr transport (data not shown) and are thus ideally suited to study Cr transport following transfection with a mammalian expression vector encoding the human CrT that is tagged with a myc epitope. AU, arbitrary units. The changes in Vmax of transport observed in response to AICAR or Cr content in growth medium correlate with changes in the total content of CrT-myc protein isolated from the corresponding HL-1 cultures.
Normalized Vmax values (Table 1) were compared with the optical density of the 60-kDa, CrT-myc band (see Fig 4B) . A high positive correlation coefficient (r) of 0.96 (R 2 ϭ 0.92, P Ͻ 0.05, N ϭ 6) was determined between Vmax and total CrT-myc protein using the Pearson correlation method. We demonstrate that substrate availability and incubation with AICAR change Cr transport in RNCM with the native transporter. The effect of AICAR was independent of medium condition. Increased phospho-ACC levels (a downstream target of AMPK) following AICAR incubation demonstrated activation of the AMPK pathway. To expand on these observations, we used HL-1 cells to show that changes in V max are correlated with CrT protein content ( Table 2) ; AMPK activation by AICAR increased V max and the amount of CrT protein located at the cell surface. Cr supplementation diminished V max and CrT protein content, whereas Cr depletion increased V max and CrT protein content. The latter results are in agreement with an earlier report describing changes in the V max for Cr transport in intact hearts isolated from rats fed diets either enriched with or depleted of Cr (3).
In transfected HL-1 cells, translation of the human CrT message is solely under the control of the cytomegalovirus promoter. There are no known native CrT gene transcription regulatory elements. Therefore, the changes in Cr transport are most likely secondary to regulatory pathways that modulate CrT protein content in the cell membrane or change its stability and trafficking. Alterations in membrane residence time of the CrT protein could require posttranslational modification(s) of the transporter protein itself (phosphorylation, ubiquitination), interactions with a yet-to-be-identified intracellular protein(s), or a combination of both types of events. The incremental response in Cr transport to growth in Cr-depleted medium or sustained AICAR incubation (Fig. 2) could reflect the time required for the cell to increase production of a CrT-interacting protein whose association is required to increase the half-life of CrT protein in the membrane.
Incubation of HL-1 cells in the presence of compound C and inhibitor of AMPK resulted in a modest reduction in Cr transport. However, compound C prevented the AICAR-induced increase in Cr transport (Fig. 4) . These results are consistent with previous studies reporting low basal AMPK activity in normal cardiomyocytes (1) . Activation of AMPK, as observed during ischemia, could enhance Cr transport and increase Cr availability, which could enhance the potentially cardioprotective effect of AMPK activation that is observed after cardiac injury (1, 12, 17) .
Our observation that AMPK activation increases Cr transport in both primary and immortalized cultured cardiomyocytes is opposite to what is reported in kidney cells and Xenopus oocytes (2) . In these cells, Cr transport is decreased by AMPK activation. This raises the possibility that AMPK's modulation of Cr transport varies by cell type. Indeed, mTOR (18), a well-characterized element in AMPK's downstream signaling cascade (7) , is proposed to mediate the decreases in Cr transport in Xenopus oocytes and renal cells following pharmacological activation of AMPK. These authors suggested a mechanism of effect mediated by serum-and glucocorticoiddependent kinase 1 and phosphorylation of a yet-to-be-identified CrT-interacting protein along with the generation of Pi (3,5)P 2 (20) . AMPK activation appears to downregulate mTOR, and treatment of oocytes and renal cells with the inhibitor of mTOR, rapamycin, decreases Cr transport (10, 13, 20) . However, treatment of our RNCM cultures with rapamycin did not alter Cr transport significantly (Fig. 6) . Elucidation of the signaling network involved in the modulation of cardiac Cr transport warrants further study; in particular, why does AMPK have different effects in cardiomyocytes compared with other cell types?
In conclusion, we demonstrate that both substrate availability and AMPK modulate Cr transport in cultured cardiomyocytes by changing the V max for Cr transport through signaling cascades that alter transporter protein content in the cell membrane. In cardiomyocytes, AMPK may serve as a positive and physiological regulator of Cr transport to help ensure that sufficient quantities of Cr are available to support myocellular function when cardiomyocytes are stressed.
